Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies

HepaRG cells, a newly developed human hepatoma cell line, differentiate into hepatocyte-like morphology by treatment with dimethyl sulfoxide (DMSO). The expression of cytochrome P450 (P450) enzymes, transporter proteins, and transcription factors was stable in differentiated HepaRG cells over a period of 6 weeks when cultured with DMSO. Compared with human hepatocytes, expression of P450 in HepaRG cells was in general lower with the exception for a considerably higher expression of CYP3A4 and CYP7A1. The expression of P450s generally decreased when DMSO was removed from the medium, whereas transporters and liver-specific factors were unaffected. The relative mRNA content of drug-metabolizing P450s displayed the highest resemblance between human hepatocytes and differentiated HepaRG cells 1 day after removal of DMSO from the medium. The metabolism of midazolam, naloxone, and clozapine in HepaRG cells was similar to human hepatocytes, indicating the function of CYP3A4, CYP1A2, and UDP-glucuronosyltransferase enzymes. However, the metabolism of 7-ethoxycoumarin and dextromethorphan was low, confirming low levels of CYP2E1 and CYP2D6 in HepaRG cells. The P450 probe substrates indicate a decrease in CYP1A2, CYP2B6, CYP2C9, and CYP3A4 activities in HepaRG cells 1 day after removal of DMSO from the medium. The activities were then relatively stable in DMSO-free medium for up to 14 days. Based on the stable expression of liver-specific functions over a long period in culture, the relative mRNA content of drug-metabolizing P450s, and metabolic properties, HepaRG cells provide a valuable in vitro model for human drug metabolism studies.

[1]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[2]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[3]  H. Yamazaki,et al.  7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. , 1996, Biochemical pharmacology.

[4]  D. Waxman,et al.  Use of 7-ethoxycoumarin to monitor multiple enzymes in the human CYP1, CYP2, and CYP3 families. , 1998, Methods in molecular biology.

[5]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[6]  O. Olesen,et al.  Contributions of Five Human Cytochrome P450 Isoforms to the N‐demethylation of Clozapine In Vitro at Low and High Concentrations , 2001, Journal of clinical pharmacology.

[7]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[8]  B. Drénou,et al.  Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor , 2007, Hepatology.

[9]  P. Quinn,et al.  Dimethyl sulphoxide: A review of its applications in cell biology , 1994, Bioscience reports.

[10]  M. Finel,et al.  Prominent but Reverse Stereoselectivity in Propranolol Glucuronidation by Human UDP-Glucuronosyltransferases 1A9 and 1A10 , 2006, Drug Metabolism and Disposition.

[11]  Olivier Fardel,et al.  Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  M. Nishimura,et al.  Effects of dimethyl sulfoxide on the gene induction of cytochrome P450 isoforms, UGT-dependent glucuronosyl transferase isoforms, and ABCB1 in primary culture of human hepatocytes. , 2003, Biological & pharmaceutical bulletin.

[13]  D. Greenblatt,et al.  Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A , 1998, The Journal of pharmacy and pharmacology.

[14]  R. Laufer,et al.  DETERMINATION OF DRUG GLUCURONIDATION AND UDP-GLUCURONOSYLTRANSFERASE SELECTIVITY USING A 96-WELL RADIOMETRIC ASSAY , 2005, Drug Metabolism and Disposition.

[15]  R. Riley,et al.  Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[16]  A. Mori,et al.  UDP-GLUCURONOSYLTRANSFERASE 1A4 POLYMORPHISMS IN A JAPANESE POPULATION AND KINETICS OF CLOZAPINE GLUCURONIDATION , 2005, Drug Metabolism and Disposition.

[17]  P. Beaune,et al.  Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.

[18]  Tommy B. Andersson,et al.  HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans , 2008, Drug Metabolism And Disposition.

[19]  D. Waxman,et al.  Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes. , 2004, Archives of biochemistry and biophysics.